Phenotypes associated with this allele

• Allele Symbol: Tg(Ins2-NP)25-3Olds
• Allele Name: transgene insertion 25-3, Michael BA Oldstone, MD
• Allele ID: MGI:3573697
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Stat4^tm1Gru/Stat4^tm1Gru Tg(Ins2-NP)25-3Olds/0	involves: 129S2/SvPas * BALB/c * C57BL/6	MGI:3620118
tg2	Tg(Ins2-NP)25-3Olds/0	involves: BALB/c * C57BL/6	MGI:3618925

Genotype
MGI:3620118

cx1

• Allelic Composition: Stat4^tm1Gru/Stat4^tm1Gru; Tg(Ins2-NP)25-3Olds/0
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

insulitis ( J:107047 )

• mutants have a lower degree of insulitis

abnormal cytotoxic T cell physiology ( J:107047 )

• a 5-fold reduction in LCMV-specific CTL precursors is seen after viral challenge with LCMV

decreased interferon-gamma secretion ( J:107047 )

• splenocytes are unresponsive to IL-12 stimulation and do not produce significant levels oi IFNgamma

decreased susceptibility to autoimmune diabetes ( J:107047 )

• a significant reduction in CD4+ T cell-dependent (2 consecutive measures of blood glucose >250 mg/dl) diabetes incidence is observed in mutants (30%) versus controls (85%) when infected with LCMV to induce IDDM

endocrine/exocrine glands

insulitis ( J:107047 )

• mutants have a lower degree of insulitis

hematopoietic system

abnormal cytotoxic T cell physiology ( J:107047 )

• a 5-fold reduction in LCMV-specific CTL precursors is seen after viral challenge with LCMV

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
type 1 diabetes mellitus		DOID:9744	OMIM:222100	J:107047

Genotype
MGI:3618925

tg2

• Allelic Composition: Tg(Ins2-NP)25-3Olds/0
• Genetic Background: involves: BALB/c * C57BL/6

homeostasis/metabolism

increased circulating glucose level ( J:81284 , J:81287 )

• 3% of transgenic mice develop diabetes when followed for 10-12 months (J:81284)

• 93% of transgenic mice develop diabetes (hyperglycemia of >250 mg/dl glucose and islets infiltrated with mononuclear cells) after being infected with LCMV (J:81284)

• mice are considered diabetic after a blood glucose measure of >300 mg/dl (J:81287)

decreased circulating insulin level ( J:81287 )

• hypoinsulinemia is exhibited by transgenic mice accompanying increased glucose levels and islet infiltration

endocrine/exocrine glands

abnormal pancreatic islet morphology ( J:81284 , J:81287 )

• pancreata of diabetic transgenic mice show swollen islets with a ground glass appearance (J:81284)

• mononuclear cells begin infiltrating the islets 10 days after viral challenge and are apparent in most transgenic mice after 30 days (J:81284)

• Background Sensitivity: after viral challenge, mononuclear cells infiltrate the islets of transgenic mice bred onto a BALB/c background at 14-21days, while mice bred onto a C57BL/6 background show infiltrates at 21-60 days (J:81284)

immune system

decreased susceptibility to autoimmune diabetes ( J:81287 )

• depletion of CD8+ lymphocytes with a monoclonal antibody inhibited development of diabetes

increased susceptibility to autoimmune diabetes ( J:81287 )

• 3% of transgenic mice develop diabetes when followed for 10-12 months

• 93% of transgenic mice develop diabetes (evidenced by hyperglycemia with glucose levels of >300 mg/dl and islets infiltrated with mononuclear cells) after being infected with LCMV

• Background Sensitivity: after viral (LCMV) challenge, transgenic mice bred onto a C57BL/6 background develop diabetes in 3-5 months, whereas transgenic mice bred onto a BALB/c background develop diabetes sooner, at 1-2 months

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
type 1 diabetes mellitus		DOID:9744	OMIM:222100	J:81284